Pancreatic adenosquamous carcinoma

Pancreatic adenosquamous carcinoma is a rare and aggressive epithelial neoplasm within the spectrum of pancreatic ductal carcinomas, characterized by the coexistence of an adenocarcinomatous component and a squamous component. Compared with conventional pancreatic ductal adenocarcinoma, this histologic variant tends to have a less favorable biological behavior, with a greater propensity for local invasion and early recurrence and generally shorter median survival in clinical series, although outcomes vary considerably according to stage, resectability and access to multimodal treatment.

Clinically, the disease often presents with a picture indistinguishable from pancreatic ductal carcinoma, dominated by obstructive jaundice in tumors of the pancreatic head, epigastric or back pain, weight loss and anorexia. Because the histologic subtype is rare, it cannot be reliably recognized clinically in advance; diagnosis rests on dedicated imaging, histologic confirmation when indicated, and accurate multidisciplinary assessment of disease extent and resectability.

When the disease is resectable, treatment is based on oncologic surgery integrated with systemic therapy according to pancreatic cancer principles, with particular attention to the frequent need for neoadjuvant strategies in borderline-resectable or locally advanced cases. In metastatic disease, management centers on systemic chemotherapy, symptom control, biliary drainage when required and nutritional support, with close monitoring for thromboembolic complications and cancer cachexia.

The epidemiology of pancreatic adenosquamous carcinoma is defined by its rarity. In major surgical series and cancer registries, this histologic subtype accounts for a small fraction of exocrine pancreatic carcinomas. Its true frequency may be underestimated for two reasons: small biopsies may not adequately sample the squamous component, and in advanced cases comprehensive histologic typing is not always obtained. Consequently, much of the available evidence comes from small retrospective series, with variability among centers and classification systems.

Demographically, the disease most often affects adults and older people, with a sex distribution similar to that of pancreatic ductal carcinoma. The pancreatic head is the most common site, consistent with the frequent presentation with obstructive jaundice; however, the tumor may arise in any pancreatic segment. Diagnosis is often made at a locally advanced or metastatic stage because of its aggressive biology and delayed recognition, as early symptoms are nonspecific.

The etiologic causes specific to adenosquamous carcinoma have not been established. No exposure has been demonstrated to be necessary and sufficient to cause this histologic variant. Clinical attention therefore shifts to risk factors shared with pancreatic ductal carcinoma, which increase the likelihood of developing exocrine pancreatic neoplasms but do not specifically explain squamous differentiation.

The most firmly established risk factors for exocrine pancreatic carcinoma include smoking, chronic pancreatitis, long-standing diabetes and certain hereditary conditions associated with a predisposition to pancreatic cancer. Obesity and metabolic syndrome contribute to risk through systemic inflammatory and metabolic mechanisms. In familial cases or in individuals with a suggestive personal and family history, genetic assessment may be indicated to identify predisposing syndromes that alter prevention and management, although the adenosquamous variant does not itself define a specific syndrome.

For pancreatic adenosquamous carcinoma, there is no population screening. The overall low incidence of pancreatic neoplasms, lack of sufficiently accurate noninvasive tests and often rapid disease course make generalized screening unsustainable. Early detection therefore remains based on recognition of suggestive symptoms and appropriate use of dedicated imaging.

A separate issue is surveillance of high-risk individuals, which is designed not for this specific histologic subtype but for the increased risk of pancreatic cancer in general. In people with predisposing hereditary syndromes or a strong family history, surveillance at dedicated centers using MRI and endoscopic ultrasonography may permit earlier identification of preinvasive lesions or early-stage tumors. In these programs, histologic typing of any tumor detected occurs only after a lesion has been identified and cannot be predicted in advance.

After treatment with curative intent, post-treatment surveillance is essential because of the high recurrence risk typical of pancreatic carcinomas. The strategy combines clinical assessment, laboratory monitoring and periodic imaging, with frequency adjusted according to pathologic stage, resection margins, lymph-node involvement and treatments received. The practical aims are early detection of clinically meaningful locoregional or metastatic recurrence and management of long-term nutritional and metabolic complications.

The biology of pancreatic adenosquamous carcinoma lies within the spectrum of pancreatic ductal carcinoma, but has distinctive features related to squamous differentiation. The adenocarcinomatous component frequently shares genetic alterations typical of ductal carcinomas, including driver mutations and dysregulation of signaling pathways that promote proliferation, invasiveness and treatment resistance. The squamous component may reflect epithelial plasticity, whereby differentiation programs and phenotypic transition produce a more aggressive pattern with greater genomic instability and a more inflammatory and desmoplastic microenvironment.

A plausible pathogenetic model views the squamous component as arising from the ductal component through metaplasia or transdifferentiation rather than as a collision between two independent tumors. This interpretation is supported in many series by shared molecular alterations in the two components and morphologic continuity in transition areas. The clinical consequence is an often more aggressive tumor, with a tendency toward necrosis, rapid growth and a greater likelihood of early systemic progression.

Histologically, diagnosis requires identification of both components. In many pathologic definitions, the squamous component is considered significant when it constitutes a substantial proportion of the tumor, because small foci of squamoid differentiation may also occur in otherwise conventional ductal carcinomas. Squamous morphology includes intercellular bridges and variable keratinization; the ductal component shows infiltrating glandular structures within desmoplastic stroma. Necrosis and a high mitotic index may be more conspicuous than in conventional ductal carcinoma.

Pathologic features useful for confirming the histologic subtype and guiding management

• Presence of an infiltrating ductal adenocarcinomatous component associated with a squamous component meeting consistent morphologic criteria.
• Extensive sampling of the surgical specimen to quantify both components and reduce the risk of underestimation.
• Supportive immunohistochemistry with squamous markers when needed and panels to exclude alternative neoplasms.
• Assessment of perineural and lymphovascular invasion, margin status and lymph-node burden, which are crucial prognostic features.

The pancreatic tumor microenvironment, typically desmoplastic, contributes to treatment resistance and impaired intratumoral vascular perfusion. In the adenosquamous variant, the squamous component may be associated with a more pronounced inflammatory profile and with hypoxia and necrosis, affecting aggressiveness and therapeutic response. Molecular characterization, when available, may be particularly useful in advanced disease to identify rare actionable alterations or DNA-repair defects that modify systemic treatment.

The clinical manifestations of pancreatic adenosquamous carcinoma generally overlap with those of ductal carcinoma. Tumors of the pancreatic head often present with obstructive jaundice, dark urine, pale stools and pruritus, sometimes accompanied by low-grade fever or cholangitis. Epigastric pain radiating to the back is common and reflects perineural invasion and capsular tension. Unintentional weight loss and anorexia are common and may precede diagnosis by weeks or months.

A subgroup of patients has symptoms related to exocrine and endocrine dysfunction, such as steatorrhea, bloating and new-onset diabetes or rapid worsening of pre-existing diabetes. Deep-vein thrombosis or migratory thrombophlebitis may be paraneoplastic manifestations and, in pancreatic carcinomas generally, signal a high thromboembolic risk. Advanced disease may cause persistent pain, severe asthenia, ascites, respiratory symptoms or hepatomegaly due to metastases.

On physical examination, findings may include jaundice, loss of muscle mass, epigastric tenderness and, in advanced cases, a palpable mass or ascites. Clinical findings cannot reliably distinguish the adenosquamous subtype, making integration with imaging and pathologic confirmation essential when indicated.

Clinical presentations that most commonly prompt a pancreatic diagnostic work-up

• Progressive obstructive jaundice with dark urine and pruritus, particularly in tumors of the pancreatic head.
• Persistent epigastric or back pain associated with weight loss and reduced appetite.
• New-onset diabetes in adulthood or rapid deterioration of glycemic control.
• Signs of malabsorption with steatorrhea and weight loss in the absence of another evident cause.
• Unexplained thromboembolic events in the setting of systemic or abdominal symptoms.

Overall, the clinical picture raises suspicion of a pancreatic neoplasm, but histologic definition and radiologic staging are essential for correctly planning treatment.

The diagnostic work-up of pancreatic adenosquamous carcinoma begins with clinical and biochemical suspicion of pancreatobiliary disease and proceeds with dedicated imaging to define the mass, disease extent and resectability. In patients with jaundice, laboratory tests typically show cholestasis with increased bilirubin and alkaline phosphatase; the CA 19-9 level may be elevated, but it is nonspecific and must be interpreted cautiously, especially in the presence of undrained cholestasis.

Contrast-enhanced CT using a pancreatic protocol is the cornerstone of staging and treatment planning because it assesses tumor size, infiltration of peripancreatic planes, relationships with the main arteries and veins, and hepatic or peritoneal metastases. MRI and MRCP are useful complementary examinations, particularly for characterizing the pancreatic duct and biliary tract, evaluating indeterminate liver lesions and improving definition of certain tissue features. In clinically significant obstructive jaundice, endoscopic biliary decompression with stent placement may be required before chemotherapy or, in selected settings, before surgery.

Histologic confirmation is indicated when the result will alter management, especially in locally advanced or metastatic disease when systemic therapy is planned. Endoscopic ultrasonography with fine-needle aspiration or core biopsy permits targeted sampling, but the adenosquamous variant carries an intrinsic risk of underestimating the squamous component because of sampling limitations. Therefore, when ductal carcinoma is diagnosed on a small specimen in the presence of aggressive clinical and radiologic features, expert pathologic review and adequate sampling are particularly important.

Definitive diagnosis on the surgical specimen requires extensive sampling and complete reporting of histologic subtype, grade, margins, perineural and lymphovascular invasion, and lymph-node status. Immunohistochemistry may support identification of the squamous component and aid the differential diagnosis with rare neoplasms or metastases, but diagnosis remains primarily morphologic. Molecular assessment may also be considered in advanced disease, particularly to identify DNA-repair defects or other alterations with therapeutic implications.

According to oncology guidelines for exocrine pancreatic carcinoma, diagnosis and treatment planning require:

Rational sequence of investigations for suspected pancreatic carcinoma

• Dedicated pancreatic-protocol CT to define the mass, vascular relationships and metastases.
• MRI or MRCP when useful for the biliary tract, liver and characterization of indeterminate lesions.
• Multidisciplinary assessment of resectability and the indication for neoadjuvant therapy or upfront surgery.
• Histologic confirmation with EUS-FNA or EUS-FNB when required before systemic therapy or when the tumor is not clearly resectable.
• Complete staging and planning of biliary drainage when indicated to ensure treatment safety and effectiveness.

In summary, diagnosis is built on high-quality imaging, rigorous definition of resectability, histologic confirmation when required and complete pathologic reporting, with awareness of sampling limitations in detecting the squamous component.

The staging of pancreatic adenosquamous carcinoma follows that of exocrine pancreatic carcinomas because it is a variant of ductal carcinoma. The most widely used international system is the AJCC/UICC TNM system (8th edition), which integrates tumor size and local extent, lymph-node involvement and distant metastases. In parallel, in clinical practice, the definition of resectability based on the relationship to major vessels is decisive in selecting upfront surgery, neoadjuvant therapy or palliative systemic treatment.

The prognosis is generally unfavorable and, in available series, often worse than that of conventional stage-matched ductal carcinoma; it depends strongly on disease extent at diagnosis, completeness of surgical resection, lymph-node burden and response to chemotherapy. Positive margins, perineural invasion and early dissemination increase the risk of recurrence. Nevertheless, in resectable cases managed with multimodal treatment, some patients achieve meaningful disease control; prompt identification and referral to high-volume centers therefore remain crucial.

Stage groups for exocrine pancreatic carcinoma (AJCC/UICC 8th edition)

• Stage 0: intraepithelial neoplasia or carcinoma in situ confined to the ducts (Tis), with no regional lymph-node metastases (N0) and no distant metastases (M0).
• Stage IA: tumor confined to the pancreas with a maximum diameter of ≤2 cm (T1), with no regional lymph-node metastases (N0) and no distant metastases (M0).
• Stage IB: tumor confined to the pancreas with a maximum diameter of >2 cm and ≤4 cm (T2), with no regional lymph-node metastases (N0) and no distant metastases (M0).
• Stage IIA: tumor confined to the pancreas with a maximum diameter of >4 cm (T3), with no regional lymph-node metastases (N0) and no distant metastases (M0).
• Stage IIB: tumor confined to the pancreas measuring ≤2 cm (T1), >2 cm and ≤4 cm (T2), or >4 cm (T3), with regional lymph-node metastases in 1–3 nodes (N1) and no distant metastases (M0).
• Stage III: tumor confined to the pancreas measuring ≤2 cm (T1), >2 cm and ≤4 cm (T2), or >4 cm (T3), with regional lymph-node metastases in ≥4 nodes (N2) and no distant metastases (M0), or tumor involving major arterial vessels (T4), with any regional lymph-node status (any N) and no distant metastases (M0).
• Stage IV: tumor of any local extent (any T), with any regional lymph-node status (any N) and distant metastases present (M1).

Overall, prognosis is determined primarily by stage and resectability, but also by the aggressive biology of this histologic subtype, which often warrants an early, intensive approach integrating systemic therapy, together with active management of cachexia, pain and thromboembolic risk.

Treatment of pancreatic adenosquamous carcinoma is based on a multimodal strategy analogous to that used for ductal carcinoma, with adjustments for its aggressiveness and frequent advanced presentation. In resectable disease, surgery is the only potentially curative option, but is rarely sufficient by itself. Resection should be performed at a high-volume center, with the goals of negative margins and adequate lymph-node staging. The procedure depends on tumor location: pancreaticoduodenectomy for tumors of the head and distal pancreatectomy for tumors of the body or tail.

In borderline-resectable or locally advanced disease, neoadjuvant therapy is often considered to increase the probability of an R0 resection and select patients with more favorable tumor biology. Chemotherapy regimens follow evidence established for pancreatic cancer, using multidrug schedules in fit patients and more tolerable alternatives in frail individuals. After surgery, adjuvant therapy is generally indicated, unless contraindicated, to reduce the risk of early systemic recurrence.

In metastatic disease, the aim is to control progression and symptoms. Systemic chemotherapy is the cornerstone and is tailored to performance status and comorbidities. Relief of jaundice by biliary drainage improves quality of life and permits safe delivery of therapy. Nutritional support, pain management and prevention of thromboembolism are crucial in practice because weight loss and sarcopenia reduce treatment tolerance and worsen prognosis.

Treatment goals and options according to the clinical setting

• Resectable disease: oncologic surgery with curative intent followed by adjuvant systemic therapy whenever possible.
• Borderline-resectable or locally advanced disease: neoadjuvant therapy with reassessment of resectability and surgery in selected responders.
• Metastatic disease: systemic chemotherapy, biliary drainage when required, pain control and nutritional support.
• Integrated supportive care: management of cachexia, prevention and treatment of thromboembolic events, and early palliative care in advanced disease.

Radiotherapy may be considered in selected settings for local control, symptom relief or consolidation after response to systemic therapy, based on multidisciplinary assessment. Treatment selection must always integrate oncologic goals with clinical feasibility because nutritional frailty and biliary or gastrointestinal complications often determine treatment adherence.

Follow-up and post-treatment surveillance after curative-intent therapy follow the principles used for pancreatic carcinoma, with particular attention to the high risk of recurrence during the first years. Surveillance combines clinical visits, nutritional and metabolic assessment, laboratory monitoring and periodic imaging. Contrast-enhanced CT of the chest and abdomen is commonly used to detect locoregional recurrence or hepatic and pulmonary metastases.

Monitoring of CA 19-9 may be used as an adjunct when it was elevated at baseline, bearing in mind that it is nonspecific and may rise with cholestasis or inflammation. In patients who have undergone pancreaticoduodenectomy, follow-up also includes management of digestive sequelae and exocrine and endocrine pancreatic insufficiency. The frequency of assessments is tailored to pathologic stage, margin status and lymph-node burden, using a pragmatic approach aimed at detecting clinically meaningful recurrence and preserving quality of life.

In patients treated for advanced disease, follow-up focuses on assessment of response and chemotherapy toxicity, with imaging at appropriate intervals and active monitoring of pain, weight, liver function and thromboembolic complications. Early integration of palliative care improves symptom control and continuity of treatment.

Long-term quality-of-life considerations for patients with pancreatic adenosquamous carcinoma depend on the interaction between surgical outcomes, the effects of systemic therapy and disease progression. In operated patients, digestive sequelae may include early satiety, altered bowel habits, malabsorption and weight loss. Exocrine pancreatic insufficiency is common and requires pancreatic enzyme replacement therapy and structured dietary support to reduce steatorrhea, vitamin deficiencies and sarcopenia.

Endocrine insufficiency, with postoperative diabetes or worsening of pre-existing diabetes, affects independence, physical activity and day-to-day management; dedicated diabetes follow-up is essential. Chemotherapy-induced neuropathy, fatigue and gastrointestinal adverse effects associated with multidrug regimens may persist and require rehabilitation strategies, symptom control, and adaptation of work and daily activities. The psychological burden is also important, because the perceived high risk of recurrence and the need for frequent assessments increase anxiety and distress.

Multidisciplinary care involving oncology, surgery, clinical nutrition, pain medicine and psycho-oncology helps preserve function and quality of life, supports adherence to treatment and ensures continuity of care over time.

Complications of pancreatic adenosquamous carcinoma result from local progression, systemic dissemination and treatment effects. Biliary obstruction with jaundice and cholangitis is common in tumors of the pancreatic head and requires prompt drainage. Severe pain caused by perineural invasion and compression of the celiac plexus may be disabling and sometimes requires neurolytic procedures in addition to analgesic treatment. Cancer cachexia and malnutrition impair performance status and chemotherapy tolerance, while thromboembolic risk is high and may produce clinically significant events.

After surgery, complications include pancreatic fistula, fluid collections, infections, bleeding and delayed gastric emptying, potentially resulting in prolonged hospitalization and the need for intensive nutritional support. In the long term, exocrine and endocrine pancreatic insufficiency are major functional complications. In metastatic disease, liver metastases may lead to hepatic failure, ascites and general deterioration, whereas peritoneal metastases may cause subacute obstruction and refractory pain.

• Biliary complications: obstructive jaundice, cholangitis, stent dysfunction and the need for repeat endoscopic procedures.
• Postoperative complications: pancreatic fistula, infections, abdominal fluid collections, delayed gastric emptying and bleeding.
• Chemotherapy toxicity: neutropenia, fatigue, peripheral neuropathy, diarrhea and nausea, affecting continuity of treatment.
• Systemic complications: venous thromboembolism, cachexia, sarcopenia and exocrine and endocrine pancreatic insufficiency.

Prevention and management of complications rely on prompt diagnosis, appropriate biliary drainage, early nutritional support, multimodal pain control and close monitoring during systemic therapy. In advanced disease, early integration of palliative care optimizes symptom control and continuity of care.